The liver contains large amounts of microRNA-122 (miR-122), whereas other tissues contain only marginal amounts of this miRNA. MicroRNAs have also been found to circulate in the blood in a cell-free form; their potential as readily accessible disease markers is currently evaluated. Here, we investigated if the serum levels of miR-122 might be useful as disease parameter in patients with chronic hepatitis C virus (HCV) infection.
INTRODUCTION
MicroRNAs (miRNAs) are evolutionarily conserved, small (18 -25 ribonucleotides) non-coding RNAs and have important roles in the control of many biological processes, such as cellular development, diff erentiation, proliferation, apoptosis, and metabolism ( 1 ) . Th ey are implicated in pathogenesis, diagnosis, and therapeutic aspects of viral infections, cardiovascular disease, and neurological and muscular disorders ( 2, 3 ) . Recently, an increasing number of reports showed that circulating miRNAs are detectable in serum and plasma in a form suffi ciently stable to serve as biomarkers ( 4, 5 ) . Th e levels of miRNAs in plasma and serum correlate strongly, suggesting that either plasma or serum can be used for investigation of these blood-based biomarkers ( 6 ) . Th e pattern of serum / plasma miRNAs have been found to be altered in several diseases, in particular heart disease, sepsis, malignancies, and autoimmune diseases (reviewed in ( 7 )). Th us, blood-derived miRNAs have great potential to serve as non-invasive markers for various human diseases. Th is has not been evaluated in patients with chronic hepatitis C virus (HCV) infection.
miR-122 accounts for ~ 70 % of all miRNAs species present in the liver ( 8 ) , whereas other tissues show only minor expression of this miRNA ( 9 ) . Th erefore, cell-free miR-122 in the blood should be highly specifi c for liver pathology. miR-122 is known to modulate the expression of genes involved in hepatic lipid and cholesterol metabolism ( 10, 11 ) , HCV replication ( 12, 13 ) , and apoptosis ( 14 ) . Persistent expression of miR-122 appears to be essential for maintaining the adult liver phenotype ( 9 -11 ). miR-122 is downregulated in a proportion of hepatocellular carcinomas ( 15 ) and appears to act as tumor suppressor ( 16 ) . Toxic liver injury has been shown to lead to an elevation of miR-122 in the plasma of rodents ( 17, 18 ) . A recent study indicates that miR-122 levels are enhanced in plasma from patients with hepatitis B virus infection ( 19 ) . Here, we investigated if the serum levels of this liver-specifi c miRNA correlate with disease parameters in patients with chronic HCV infection (CHC).
METHODS

Patient selection
In all, 68 therapy-naive patients, who had undergone liver biopsy for staging and grading of CHC in our hospital as well as 19 healthy control subjects were enrolled in the present prospective study. Their characteristics are summarized in Table 1 . This investigation represents a substudy of a multicenter study evaluating ultrasound-based elastography methods and serum markers for liver fibrosis in patients infected with HCV. Inclusion criteria were the consistent detection of HCV RNA ( ≥ 6 months) and positive anti-HCV antibodies by third-generation enzyme immunoassay. Exclusion criteria were co-infection with hepatitis B virus or human immunodeficiency virus types 1 and 2, liver disease of other origin than HCV infection, decompensated liver disease, organ transplantation, immune suppression, autoimmune disorders, consumption of > 20 g / day alcohol, and intravenous drug abuse within the last 6 months. The study was approved by the local Ethics Committee, and informed consent was obtained from all participants of the study. Histological assessment of liver fibrosis was performed by liver biopsy in all patients and blood samples were obtained on the day of presentation.
Liver histology
Liver biopsy specimens were fi xed in formalin and embedded in paraffi n. Sections were stained with hematoxylin -eosin and were reviewed by experienced hepatopathologists. Fibrosis stages (F0 = no fi brosis -F6 = cirrhosis) and the histologic activity index (HAI) in the liver were evaluated semiquantitatively according to the Ishak criteria ( 20 ) . Th e HAI consists of (i) periportal or periseptal interface hepatitis (piecemeal necrosis A0 -4), (ii) confl uent necrosis (B0 -6), (iii) focal lytic necrosis, apoptosis, and focal infl ammation (C0 -4), and (iv) portal infl ammation (D0 -4), resulting in a maximal score of 18.
Blood sampling
Peripheral blood was collected at the time of liver biopsy from each individual directly into serum tubes (Sarstedt, N ü mbrecht, Germany). Th e tubes were centrifuged at 1,500 g for 10 min at 4 ° C, sera were aliquoted and additionally centrifuged at 2,000 g to completely remove any remaining cells. Sera were stored at − 80 ° C until use.
Detection of miRNAs by quantitative real-time reverse-transcription polymerase chain reaction
For isolation of RNA from serum 50 μ l homogenate additive (miRVana RNA isolation kit; Ambion-ABI, Austin, TX) and 250 μ l lysis buff er (miRVana RNA isolation kit) were added to 500 μ l of serum sample and incubated on ice for 10 min. RNA extraction was performed with TriReagentLS (Sigma-Aldrich, St Louis, MO) and chloroform. Phase separation was achieved by centrifugation at 12,000 g for 15 min. Total RNA was isolated from the aqueous phase according to the mir Vana miRNA isolation kit protocol and stored at − 20 ° C.
A measure of 5 μ l of RNA was reverse transcribed using the TaqMan miRNA reverse-transcription kit and the TaqMan miRNA assay specifi c for miR-122 or miR-16 according to the instructions of the manufacturer (ABI). For real-time polymerase chain reaction (PCR), 3 μ l of cDNA was mixed with 12 μ l master mix (7.5 μ l TaqMan Universal PCR MasterMix no UNG (ABI), 3 .75 μ l H 2 O, and 0.75 μ l TaqMan MicroRNA Assay probe. Real-time PCR ALT, alanine leucine transaminase; HAI, histologic activity index.
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Serum miR-122 in Chronic Hepatitis C was performed on a StepOnePlus Real-Time PCR System (ABI). Quantitative real-time PCR was performed in duplicates. Th e cycle threshold ( C T value) is defi ned as the number of cycles required for the fl uorescent signal to cross the threshold in qPCR.
Statistical analysis
Data were analyzed using the BiAS soft ware for windows (version 9.07, Epsilon publishing, Hochheim-Darmstadt, Germany). Statistical signifi cance for correlations was determined using Spearman ' s non-parametric rank test. Th e correlation coeffi cients r were calculated using Spearman correlation. Diff erences between the two groups were evaluated using the Wilcoxon -MannWhitney U -test. P values < 0.05 were consi dered to be signifi cant.
RESULTS
The level of miR-122 is increased in sera from patients with CHC
To investigate if the serum level of miR-122 is altered in patients with CHC, we studied the levels of miR-122 in sera from 68 patients with CHC as well as 19 healthy controls. Total RNA was extracted from the sera and miR-122 was quantifi ed by real-time reversetranscription (RT) -PCR using hairpin primers. Th e C T value, that is, the number of cycles required for the fl uorescent signal to cross the threshold in qPCR, inversely correlates with the miRNA level. Th e C T value of miR-122 in sera from healthy controls signifi cantly diff ered from that in patients with CHC ( P < 0.05) ( Figure 1a ). Th ere was no correlation between the age and serum miR-122 levels ( Figure 1b ), indicating that the increased levels of miR-122 in sera from CHC patients and healthy controls cannot be attributed to the diff erent mean age of the two groups. In contrast, the serum levels of miR-16, a ubiquitous miRNA which is not specifi c for the liver, did not diff er between the patients and healthy controls ( Figure 1c ).
Serum levels of miR-122 and markers of liver injury
To explore the potential suitability of the serum level of miR-122 as disease parameter in patients with CHC, we correlated the level of miR-122 with surrogate parameters routinely used to evaluate CHC ( 21, 22 ) . Th e C T value of miR-122 in the sera negatively correlated with serum levels of alanine leucine transaminase (ALT) ( r = − 0.642, 95 % confi dence interval: − 0.83 to − 0.45, P < 0.000001) ( Figure 2a ) and aspartate transaminase (AST) ( r = − 0.522, 95 % confi dence interval: − 0.73 to − 0.31, P = 0.000007) ( Figure 2b ), that is, the serum level of miR-122 positively correlated with ALT and AST. Th e correlation between miR-122 and ALT was more pronounced than that between miR-122 and AST. Th e miR-122 serum levels also correlated with the HAI score in the liver ( r = − 0.39, 95 % confi dence interval: − 0.61 to − 0.16, P = 0.0011) ( Figure 2c ). Th ere was no correlation between the serum levels of miR-16 and any of these parameters ( Figure 3a -c ) .
Repeated measurements in the two healthy subjects over 3 days revealed reproducible values for miR-122 and ALT (see Supplementary Figure 1a and b online). Observation of miR-122 and ALT levels in sera of a CHC patient who was not under antiviral therapy showed only minor changes in both parameters over 4 months (see Supplementary Figure 1c online) .
Approximately 20 -30 % of patients with CHC show persistently normal levels of serum ALT, that is, the disease activity in these patients cannot be monitored by measuring serum ALT levels ( 23 ). In patients with persistently normal ALT levels, the serum miR-122 levels were comparable to those in sera from the healthy volunteers ( Figure 1a ) . Th ese data indicate that the serum level of miR-122 refl ects necroinfl ammatory activity in the liver in patients with CHC and elevated ALT values, but not in patients with normal ALT levels.
Serum levels of miR-122 and parameters of liver function and liver fi brosis
To investigate if the serum level of miR-122 is related to liver function, we investigated the relationship between the levels of serum miR-122 and the serum albumin concentration, international normalized ratio, and the serum bilirubin concentration. However, although there were positive trends for a positive correlation between the serum miR-122 level and the serum bilirubin concentration ( P < 0.084) ( Figure 4b ) as well as international normalized ratio ( P < 0.072) ( Figure 4c ), none of these correlations reached signifi cance ( Figure 4a -c ) , suggesting that the serum miR-122 levels did not refl ect overall liver function. We also compared miR-122 serum levels and the stage of liver fi brosis. Again, there was no correlation between the miR-122 serum level and the stage of liver fi brosis ( P = 0.168) ( Figure 4d ) .
Levels of the miR-122 and HCV RNA
Given the link between miR-122 and HCV infection ( 12,13 ), we investigated if there is a relation between the serum levels of miR-122 and serum HCV RNA. However, no such relation was found ( Figure 5 ).
DISCUSSION
Evidence is accumulating that cell-free miRNAs released from pathologically altered tissues ( 4,24,25 ), most notably tumors 
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Serum miR-122 in Chronic Hepatitis C miR-122 in serum or plasma should be more specifi c for liver diseases than ALT and AST, because miR-122 is almost exclusively expressed in the liver, whereas ALT and AST may originate from other tissues, most notably from skeletal muscle ( 28 ), reducing their diagnostic value. Further analyses revealed that the concentration of miR-122 in sera from patients with CHC correlates with the serum activities of ALT and AST as well as with the HAI score in the liver, which represents the gold standard in the assessment of hepatic infl ammation and cell damage. In contrast, the serum level of the non-liver-specifi c miR-16 does not show any diff erence between CHC patients and healthy volunteers. CHC patients with persistently normal ALT serum levels show milder disease activity and lower hepatic proliferative activity index ( 29, 30 ) . Analyses of the patients with CHC and persistently normal serum ALT activity for miR-122 serum levels revealed that the miR-122 concentration in these patients were undistinguishable from those in healthy controls. Th us, it appears that the lower disease activity in these patients does not lead to alterations of miR-122 serum levels and that the pathomechanisms leading to the increase in the concentrations of miR-122 and ALT activity are similar.
An important fi nding of the present study is that the level of serum miR-122 does not correlate with liver fi brosis, cirrhosis, and parameters of liver function. Th us, the miR-122 serum level might be a useful parameter to specifi cally monitor ongoing damage of hepatocytes irrespective of the stage of chronic hepatitis. In contrast, the intrahepatic miR-122 level negatively correlates with the fi brotic stage and serum ALT and AST activity ( 31 ) . Th us, alteration of the expression of miR-122 in the liver has no particular ( 4, 26 ) , are useful blood-based biomarkers for diseases. A recent study indicates that the release of miRNA might be a mechanism of adaptation of cells to an altered environment ( 27 ) . Th e identification of altered individual miRNAs or miRNA pattern in serum or plasma off ers the prospect of novel readily accessible biomarkers, which could be used for the assessment of diseases such as CHC. In contrast to the majority of miRNAs, miR-122 is almost exclusively expressed in the liver, rendering this miRNA particularly interesting to be exploited as biomarker for liver diseases. Th us, it was previously shown that the level of miR-122 in blood plasma increases earlier than that of ALT upon toxic liver injury in rodents ( 17, 18 impact on the serum miR-122 level. A recent study showed that carbon tetrachloride-induced acute toxic liver injury leads to an elevation of the plasma miR-122 concentration in rats ( 17, 18 ). An additional report shows a correlation between the plasma miR-122 and necroinfl ammatory activity in the liver in patients with chronic hepatitis B virus infection ( 19 ) . Together, these fi ndings indicate that the serum level of miR-122 refl ects the rate of injury and / or turnover of hepatocytes. Mechanistically, miR-122 may leak from damaged hepatocytes or may be actively exported from altered tissues as a mechanism of adaptation to alterations of the state of a cell.
Hepatic miR-122 is crucial for HCV replication and is a feasible target for drug development ( 12, 13 ) . Infection of cultured Huh-7 cells with HCV J6 / JFH reduces miR-122 levels in these cells ( 31 ) . Th us, considerable evidence suggests that miR-122 has an important role in HCV life cycle in the liver. However, miR-122 levels in the liver do not correlate with HCV load in the liver ( 31, 32 ) . In the present study, we did not observe any correlation of serum miR-122 and HCV RNA serum levels. Th ese fi ndings are in line with the weak correlation between the serum HCV level and liver histopathology ( 33 ) as well as serum ALT and AST levels ( 23, 34 ) . Th us, the relation between HCV and miR-122 in the liver and in serum appears to be complex and requires further clarifi cation.
Th e routinely used surrogate parameters to evaluate patients with CHC fail to predict the progression of hepatic necroinfl ammatory activity and fi brosis in a considerable number of patients ( 23 ). Th us, there is a need for new serum markers for staging and grading of chronic hepatitis. Th e present study provides evidence that miR-122 serum levels refl ect necroinfl ammatory activity in the liver of patients with CHC and might thus be a useful biomarker for grading of CHC and potentially other liver diseases. Nevertheless, further studies including larger and diff erent patient collectives are necessary to fully evaluate the diagnostic potential of the serum miR-122 level. Th e process of examination of serum miRNAs as diagnostic biomarkers is still at its infancy, but considering the rapid progress in this fi eld, development of miRNA-based blood diagnostics is likely to be successful in the near future. We conclude that the serum level of miR-122 strongly correlates with serum ALT activity and with necroinfl ammatory activity in patients with CHC and elevated ALT levels, but not with fi brosis stage and functional capacity of the liver. Future studies to fully elucidate the diagnostic potential of the serum miR-122 level in larger studies of CHC patients are warranted.
